Survival in XDR TB: Shifting the curve and shifting the paradigm

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 2, 2011, Pages 89-91

  Martinson, Neil A ^a,b   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIRETROVIRUS AGENT; BEDAQUILINE; DELAMANID; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG MEGADOSE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; MIXED INFECTION; MORBIDITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA;

EID: 79957946931     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31821b4b42     Document Type: Review

References (20)

1. Kvasnovsky CL, Cegielski JP, Erasmus R, et al. Extensively drug-resistant TB in the Eastern Cape, South Africa: high mortaltiy in HIV-negative and HIV-postive patients. J Acquir Immune Defic Syndr. 2011;57:146-152.
2. World Health Organization. Global Tuberculosis Control: WHO Report .2010. Geneva, Switzerland: World Health Organization; 2010.
3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580. (Pubitemid 44780738)
4. Van Rie A,Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet. 2000;356:22-25. (Pubitemid 30416990)
5. Harries AD, Hargreaves NJ, Gausi F, et al. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis. 2001;5:1000-1005. (Pubitemid 33134749)
6. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.
7. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIVinfected adults with newly diagnosed tuberculosis. Abstract THLBB106. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Austria, Vienna.
8. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-1807.
9. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-2405.
10. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:e466.
11. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009;2:215-218.
12. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009;373:1183-1189.
13. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128-138. (Pubitemid 351212403)
14. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227-230. (Pubitemid 24067929)
15. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177:787-792. (Pubitemid 351490566)
16. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363: 1005-1015.
17. Jarand J, Shean K, O'Donnell M, et al. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health. 2010;15:1179-1184.
18. Cohen T, Murray M, Wallengren K, et al. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med. 2010;7:e1000296.
19. Corbett EL, Bandason T, Duong T, et al. Comparison of two active casefinding strategies for community-based diagnosis of symptomatic smearpositive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 2010;376: 1244-1253.
20. Shapiro A, Rakgokong M, Chaisson R, et al. Targeting at-risk households: intesified case finding for TB and HIV in contacts of TB patients in South Africa. Abstract #FRLBC106. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria.